علاج النقائل العظمية في سرطان البروستاتا المقاوم للإخصاء مع النقائل العرضية

References

1. The randomized, double blind, ALSYMPCA trial included 921 patients with bone metastases from CRPC, without visceral disease, after progression to docetaxel or unfit for this agent.
2. As a result, radium-223 was approved for patients with CRPC with symptomatic metastases and without visceral disease by FDA in May 2013.
3. Radium dichloride 223 emits alpha particles, with high energy but low penetration (<100 μm or a range of 2–10 cells of diameter), and acts in the microenvironment of bone metastases.
4. Due to the potential haematological toxicity of radium 223, adequate bone-marrow function parameters — haemoglobin ≥10 g/dL, absolute neutrophil count ≥1.5 × 10⁵/L, and platelets >100 × 10⁵/L — are required.

DOI: 10.1007/s12094-016-1590-1